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a b s t r a c t
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with pal-
liative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently
recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Background
Radiotherapy is used in the treatment of approximately 40% of
cancer patients [1]. It is used as a primary treatment in combina-
tion with chemotherapy in locally advanced cancers of the head
and neck, lung, oesophagus, rectum, anus and as part of multi-
modality treatment in numerous other cancers. Standard-of-care
chemoradiation has been shown to be superior to radiation alone
in most cancers where it is used for primary treatment, at the
expense of increased normal tissue toxicity. In spite of this, tumour
control rates, and consequent survival, remain inadequate in a
number of clinical settings.
Many strategies have been investigated over recent decades to
attempt to improve outcomes with radiotherapy, including altered
fractionation, dose-escalation with the use of advanced radiother-
apy techniques, hypoxia modification and combination with tar-
geted therapies and immunotherapy [2]. These have met with
limited degrees of success.
Targeting the G2 cell cycle checkpoint is an attractive option for
selective sensitisation of tumour cells to radiation [3]. There are
multiple lines of preclinical data demonstrating that inhibiting this
checkpoint through kinase inhibition of ATR and CHK1 will sensi-
tise to radiation therapy, by increasing mitotic cell death and
reducing DNA repair [4–9]. There are currently three ATR inhibi-
tors in early clinical development, including AZD6738, an orally
bioavailable inhibitor of the ATR kinase [10]. ATR is critical in the
cellular response to DNA replication stress, the levels of which
are elevated in many cancers as a result of oncogene activation,
endogenous and exogenous DNA damage [11], and targeting this
may be a novel therapeutic strategy.
Traditionally, combination of novel agents with radiation ther-
apy has not taken place until monotherapy studies at phase I or
later have completed, with some evidence of monotherapy effect.
This study is notable for introducing radiation combination studies
early in the clinical development of AZD6738.
https://doi.org/10.1016/j.ctro.2018.06.001
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Here, we describe the clinical trial protocol of the PATRIOT
study, which combines AZD6738 monotherapy dose-escalation
and dose-expansion components with a combination phase I com-
ponent with palliative radiotherapy.
Methods and study design
PATRIOT is co-sponsored by the Royal Marsden and The Insti-
tute of Cancer Research. The study is jointly funded by Cancer
Research UK, AstraZeneca and the Experimental Cancer Medicines
Network as part of the Combinations Alliance collaborative agree-
ment. The study has been approved by the National Research
Ethics Committee (14/LO/0465). It is registered on the clinicaltri-
als.gov (NCT02223923) and EudraCT (2013-003994-84) databases.
It is a multi-centre, open-label, non-randomised phase I study
of AZD6738 in advanced solid tumours with three parts:
monotherapy dose-escalation (part A), monotherapy dose-
expansion at maximum tolerated dose (MTD) (part B), and dose-
escalation in combination with palliative radiotherapy (part C).
This design was chosen in order to gain information about
monotherapy toxicity prior to combination with radiation, to
investigate dosing schedules which would be amenable to combi-
nation with radiation combination, and improve monotherapy tol-
erability, and to gain further information about markers of
response to AZD6738.
Parts A and C of the study are 3+3 dose-escalation designs
(Figs. 1, 2). Part A has single-patient cohorts at lower dose levels,
changing to 3+3 at the first G2 toxicity. Part C initially escalates
drug dose, followed by escalation of radiation dose. It allows dose
escalation of AZD6738 with 20 Gy in 10 fractions of radiotherapy,
starting at least 2 dose-levels below the currently tolerated dose
of AZD6738. At the MTD, or a dose lower than MTD as determined
by the safety review committee, the radiation dose will be esca-
lated to 30 Gy in 15 fractions, with 10 fractions sensitised, further
cohorts will sensitise 15 fractions and expansion cohorts will add
maintenance AZD6738 until disease progression (Fig. 2).
Part C of the study will run 2 parallel tracks, stratifying by site of
irradiation into disease above and below the diaphragm, in order to
provide more meaningful information on specific toxicities. These
two tracks will be treated independently, and may result in differ-
ent recommended doses to proceed for each site of irradiation.
Total number of patients for parts A and C will depend upon the
toxicities encountered. Part B will treat a maximum of 50 patients.
Selected inclusion and exclusion criteria
Inclusion criteria
1. Histologically or cytologically documented solid tumour
without further standard therapy options.
2. Part B only: documented disease progression prior to study
entry, tumour site amenable to fresh biopsy.
3. Part C only: disease causing or likely to cause symptoms
within a short period of time such that palliative radiother-
apy is indicated or justified.
4. Evidence of measurable or evaluable disease by RECIST 1.1.
5. ECOG performance status 0–1 (part A); 0–2 (parts B and C).
6. Life expectancy of at least 3 months.
7. Adequate and stable haematological, hepatic and renal
function.
Fig. 1. study design for parts A and B.
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8. Not pregnant, using adequate contraception.
9. Willing and able to comply with scheduled visits, tissue
sampling, treatment plan, and laboratory tests.
10. Able to swallow, absorb and retain oral medication.
Exclusion criteria
1. Part C only: prior radiotherapy to the treatment site.
2. Concomitant anti-cancer therapy or investigational medical
products) (long-term hormonal therapy permitted in part C).
3. Receiving, or having received, concomitant medications,
herbal supplements and/or foods that significantly modulate
CYP3A4.
4. Pregnant or breast-feeding women.
5. Clinically significant cardiac disease.
6. Known HIV positive or active hepatitis B or C infection.
7. Uncontrolled active infection.
8. Symptomatic and progressive or steroid-requiring brain
metastases or leptomeningeal disease involvement.
9. Uncontrolled hypertension.
10. Relative hypotension or clinically relevant orthostatic
hypotension.
11. Haematuria: +++ on microscopy or dipstick.
Objectives and endpoints
The primary objective of the study is to determine the feasibil-
ity and safety of administration of AZD6738 as a single-agent and
in combination with different schedules of radiotherapy. Toxicity
will be recorded using CTCAE 4.03 criteria, and definitions of
dose-limiting toxicity are given in Table 1.
The secondary objectives are to guide dose and schedule selec-
tion for subsequent later-phase studies of AZD6738 as a single-
agent or with palliative or radical radiotherapy, to perform phar-
macokinetic analysis of plasma drug levels after single and multi-
ple doses, and to assess preliminary anti-tumour activity (by
RECIST response) of AZD6738 as a single-agent and in combination
with palliative radiotherapy.
Exploratory objectives of the study are to conduct pharmacody-
namic studies on tumour and normal tissue, and explore the value
of putative predictive biomarkers for response to AZD6378.
Study treatments
Patients will take AZD6738 tablets by mouth, twice daily. Pro-
posed dose escalation schema is shown in Table 2. Part A of the
study has continuous dosing in 28-day cycles, part B allows inter-
mittent schedules. Tumour response assessments will take place
every 2 cycles (8 weeks). During part C, participants will start tak-
ing AZD6738 three to seven days before radiotherapy starts, then
continuously through radiation, finishing two days after the final
sensitised fraction. Response assessments will take place at 4 and
8 weeks after the end of radiotherapy.
Duration of study
During the monotherapy parts of the study, participants will
continue taking AZD6738 until disease progression, unacceptable
toxicity or withdrawal of consent. During radiation, participants
will take a defined duration of AZD6738 around the course of
radiotherapy, unless in expansion cohorts, where they will con-
tinue maintenance AZD6738 until disease progression. Participants
will be followed up until acute toxicity resolves to baseline or
grade 1. Participants in part C will be followed up for late toxicity
at three-monthly intervals for one year. Where physical attendance
is not possible, telephone contact will be made with referring
oncologist or general practitioner to establish whether there is sig-
nificant late toxicity. Overall survival will not be assessed.
Data analysis
Data analysis will be descriptive, with analysis taking place at
every dose-level to inform dose-escalation decisions. Toxicity will
be graded according to CTCAE v4.03 and dose-limiting toxicities
are defined in Table 1. Late toxicity after three months from
Fig. 2. study design for part C.
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completion of treatment will be graded using LENT-SOMA scoring.
Dose-escalation decisions will be made using a dose-limiting toxi-
city (DLT) window of the first cycle (28 days) treatment for part A,
and until 2 weeks after the end of radiotherapy for part C. Signifi-
cant late toxicity will be taken into account when making dose-
escalation decisions for part C, although this has not been formally
incorporated into the study design. Dose escalation decisions are
through a safety review committee, chaired by an independent
external clinical oncologist, with a senior ECMC clinician who is
not an investigator also on the committee.
Discussion
PATRIOT is notable for integrating a radiation combination
study early in the clinical development of a drug. Drugs enhancing
radiation response are an area for potential significant gains in cure
rates with radical treatment, although cautious study design is
essential given the risk of long-term radiation toxicity [12,13].
PATRIOT attempts to gain more meaningful toxicity data from a
study treating a wide range of patients by stratifying by site of irra-
diation. The study will escalate radiation dose from 20 Gy to 30 Gy,
in 2 Gy fractions, to investigate the effect in a fractionation sched-
ule relevant to radical treatment.
Multiple biomarkers have been proposed for response to ATR
inhibitors as monotherapy or in combination in preclinical studies,
mainly loss of components of the DNA damage response or high
levels of replication stress [14]. Translational studies using mate-
rial from patients in this study will focus on potential predictive
biomarkers to ATR inhibition. We hypothesise that tumours with
a defective DNA damage response will be more likely to respond
to ATR inhibition, either with or without radiotherapy. Patients
entering part B of the study will have fresh biopsy material anal-
ysed for a number of DDR components, using DNA sequencing
and immunohistochemistry, and other participants will have
archival material analysed, if it is available.
If the combination is well tolerated, we aim to proceed to a ran-
domised study comparing standard-of-care radiotherapy or
chemoradiotherapy to the addition of AZD6738 in a patient popu-
lation treated with radical intent.
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